Thomas Darling, Ph.D.

President and CEO


Dr. Thomas Darling, President and CEO of Edunn, has managed pharmaceutical development in the US and internationally, including clinical trials, for SmithKline Beecham, Searle, and Pfizer. He has had responsibility for R&D portfolios, strategic planning, and budget. Previously he had managed biologics manufacturing scale up departments, CMC (Chemistry, Manufacturing, Controls) regulatory affairs, and at the request of the European management group of Pfizer Animal Health, joined the Business Development Group in Brussels to assist with acquisition of biologics, experience that later was demonstrated in his work to out license Deracoxib, of the Celebrex family.

Dr. Darling's industrial experience was subsequent to earning M.Phil. and Ph.D. in the Department of Molecular Biophysics and Biochemistry at Yale, and his work as an NIH postdoctoral fellow and researcher in the Department of Neurobiology, Stanford University School of Medicine. At Stanford, while working in the laboratory of Dr. Eric Shooter, Dr. Darling discovered the preproNGF ( Nerve Growth Factor Precursor Protein, also found in the brain and lack of NGF is implicated in the pathology of Alzheimer's disease); isolated and characterized the first NGF from a female of any species - Mastomys natalensis - and with a colleague sequenced its DNA. After Stanford, he joined the Veteran's Administration CNS Regeneration group in Washington, D.C., and was adjunct faculty, Department of Physiology, George Washington University, prior to entering the pharmaceutical industry.